The enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.
is expected to receive a U.S. weight loss approval for its similar drug, Mounjaro, later this year.
"We're going full guns on this," said Bill Sessa, chief scientific officer at Pfizer's Internal Medicine Research Unit. "If we can accelerate, we will." The United States is expected to account for as much as 90% of weight-loss drug sales due to the number of potential patients and higher pricing than other countries, industry analysts and executives say.
Eli Lilly is working on an oral GLP-1. Novo Nordisk already offers Rybelsus, an oral version of the same compound in Wegovy for diabetes, although its success has been limited. Doctors expect patients will need to stay on these drugs long term to maintain their weight loss. Last year, a Novo Nordisk-funded study found patients regained about two-thirds of their lost weight a year after stopping treatment.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Investors see big Novo Nordisk stock boost if obesity drug shows heart benefitPositive trial data showing Novo Nordisk’s obesity drug helps save and extend lives, not just lose weight, could propel Europe's best-performing stock even higher, according to 10 investors and industry analysts interviewed by Reuters.
Read more »
Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demandDanish drug developer Novo Nordisk said it would have to halve the supply of starter doses of its popular Wegovy weight-loss drug in the United States to cope with high demand after reporting forecast-beating results on Thursday.
Read more »
Breakingviews - Novo Nordisk’s chunky valuation risks crash dietNovo Nordisk’s weighty valuation could be headed for a crash diet. On Thursday, the maker of diabetes and obesity remedies was worth over $270 billion, twice its value only two years ago. But its untarnished bull run may be scuppered by competition from rival Eli Lilly , questions about effectiveness and market size.
Read more »
Novo Nordisk’s chunky valuation risks crash dietThe $274 bln pharma group trades at a big premium to peers. Investors are buoyed by hopes Novo can take a large share of an obesity market that could be worth $100 bln by 2031. But competition and questions about its drug’s effectiveness could slim down its valuation.
Read more »
Judge dismisses Trump's $100 million lawsuit against The New York TimesFormer President Donald Trump's $100 million dollar lawsuit against The New York Times was dismissed by a New York Supreme Court judge on Wednesday.
Read more »
Watch the 'Evil Dead Rise' in New Concept Art'Evil Dead Rise' director curleecronin has shared concept art from some of the film's most iconic moments.
Read more »